A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
Merck Sharp & Dohme LLC
Summary
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has one of the following cancers: * Unresectable or metastatic colorectal cancer. * Advanced and/or unresectable biliary tract cancer (BTC) * Hepatocellular carcinoma (HCC) not amenable to locoregional therapy * Locally advanced unresectable or metastatic gastroesophageal cancer * Has received prior therapy for the cancer. * Has recovered from any side effects due to previous cancer treatment Exclusion Criteria: The main exclusion criteria include but are not limited to the following:…
Interventions
- BiologicalPatritumab deruxtecan
Administered via intravenous (IV) infusion
Locations (62)
- UCLA Hematology Oncology Santa Monica ( Site 1205)Santa Monica, California
- University of Colorado Cancer Center ( Site 1200)Aurora, Colorado
- Sibley Memorial Hospital ( Site 1208)Washington D.C., District of Columbia
- University of Florida ( Site 1202)Gainesville, Florida
- Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213)Miami Beach, Florida
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203)Marietta, Georgia